Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
The Arkansas Regional Innovation Hub has been selected as the central Arkansas host for the 2016 InnovateHER national pitch competition from the U.S. Small Business Administration.
Carolina Cruz-Neira, director of the Emerging Analytics Center at the University of Arkansas at Little Rock, promises a show people will remember when her team hosts an open house on Oct. 16-17 to showcase the latest virtual reality technology.
An Internet entrepreneur is planning to take the insights offered by big data and the oversharing promoted by Facebook to its logical — and horrifying — conclusion: a “Yelp for people,” as it’s been called.
Rudder, 40, is the co-founder of OkCupid, one of the world's largest dating sites. He also is the author of "Dataclysm," a book that analyzes trends in social media.